The British Irish Hearing Instrument Manufacturers Association (BIHIMA) recently published Q3 2023 data on hearing instrument usage in the UK and the Republic of Ireland (ROI), highlighting a significant surge in NHS sales.
In the UK, there’s been an overall positive trend, with a 6.5% increase in private units compared to Q3 2022 and a 1.4% rise from Q2 2023. However, the most notable growth has been in the NHS market, witnessing a 20% rise from the same period last year and a substantial 29% uptick from the previous quarter.
After a significant decline in sales during Q2, the data for Q3 presents more optimistic figures, showing improvement compared to both the previous year and the last quarter. In the UK, there has been a notable overall increase in market size units, marking a 6.5% rise in private units since Q3 2022 and a 1.4% increase from Q2 2023.
Notably, the most substantial change is witnessed in the NHS market, with volumes surging by 20% over the same period in 2022 and experiencing an impressive 29% increase in the last quarter.
Rechargeable hearing instrument sales have continued to edge up this quarter in the UK, whilst in the ROI they have remained at a similar level. Despite this, ROI has experienced a 7.5% uplift across-the-board compared to the previous quarter.
“We’re happy to see an increase in Irish hearing market data because it adds to a promising landscape throughout the quarter. While we did experience an unprecedented decline last quarter, overall, the year has been strong, consistent and positive. We look forward to seeing how this develops into quarter four.”
–Paul Surridge, BIHIMA Chairman
BIHIMA represents the hearing instrument manufacturers of Britain and Ireland, working in partnership with other professional, trade, regulatory and consumer organisations within the health care and charitable sectors. We raise consumer awareness about the latest hearing technology and aim to influence government and policy makers to improve the lives of people with hearing difficulties.